Incyte advertising spend, FY2025
Incyte (INCY) reported $156M of advertising expense for the fiscal year ended Dec 31, 2025. That is 3.0% of revenue of $5.1B. Down 22.3% from FY2024. Formerly Incyte Genomics and Incyte Pharmaceuticals.
Key facts
- Ad spend is 5.4x its FY2020 level ($28.9M), faster than revenue (1.9x).
- The highest year on file is FY2023 at $222M; FY2025 is 30% below it.
- Largest increase +197.6% in FY2022; largest cut -22.3% in FY2025.
- Ad spend has fallen 2 years in a row.
- Ad spend is 3.0% of revenue, up from 1.1% in FY2020.
- Incyte spends more on advertising than 43% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is below the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 11.3% of selling, general and administrative expense. Research and development spending was 13x advertising. Advertising equalled 10.3% of operating income.
| Advertising | $156M | AdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $1.4B | ad spend = 11.3% |
| Research and development | $2.1B | R&D = 13x ad spend |
| Operating income | $1.5B | ad spend = 10.3% |
| Net income | $1.3B |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156M | -22.3% | $5.1B | 3.0% | AdvertisingExpense | 10-K Feb 10, 2026 |
| FY2024 | Dec 31, 2024 | $201M | -9.6% | $4.2B | 4.7% | AdvertisingExpense | 10-K Feb 10, 2026 |
| FY2023 | Dec 31, 2023 | $222M | +13.0% | $3.7B | 6.0% | AdvertisingExpense | 10-K Feb 10, 2026 |
| FY2022 | Dec 31, 2022 | $196M | +197.6% | $3.4B | 5.8% | AdvertisingExpense | 10-K Feb 10, 2025 |
| FY2021 | Dec 31, 2021 | $66M | +128.4% | $3B | 2.2% | AdvertisingExpense | 10-K Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $28.9M | +88.9% | $2.7B | 1.1% | AdvertisingExpense | 10-K Feb 7, 2023 |
| FY2019 | Dec 31, 2019 | $15.3M | +44.3% | $2.2B | 0.7% | AdvertisingExpense | 10-K Feb 8, 2022 |
| FY2018 | Dec 31, 2018 | $10.6M | n/a | $1.9B | 0.6% | AdvertisingExpense | 10-K Feb 9, 2021 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Incyte in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 258 | Wolverine World Wide | $158M | 8.4% | +12.7% | FY2025 |
| 259 | Freshpet | $158M | 14.3% | +23.6% | FY2025 |
| 260 | Petco Health & Wellness | $158M | 2.6% | +1.1% | FY2026 |
| 261 | Incyte | $156M | 3.0% | -22.3% | FY2025 |
| 262 | Simon Property Group | $156M | 2.4% | +7.8% | FY2025 |
| 263 | eHealth | $154M | 27.7% | -6.5% | FY2025 |
| 264 | Scotts Miracle-Gro | $152M | 4.5% | +8.0% | FY2025 |
Questions
How much does Incyte spend on advertising?
Incyte spent $156M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 10, 2026.
What percentage of revenue does Incyte spend on advertising?
3.0% of revenue in fiscal 2025 ($156M against $5.1B). The median across the 458 companies tracked is 4.5%.
Is Incyte spending more on advertising?
No. Ad spend fell 22.3% in fiscal 2025 from fiscal 2024. It has fallen 2 years in a row.
How does Incyte rank by advertising spend?
#261 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Incyte spend more on advertising than on R&D?
No. In fiscal 2025 it spent $2.1B on research and development and $156M on advertising.
What does Incyte's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 10, 2026
- Accession number
0000879169-26-000010- Company
- INCYTE CORP, CIK 879169, SIC 8731 (Services-Commercial Physical & Biological Research)
- Former names
- Incyte Genomics, Incyte Pharmaceuticals
- Headquarters
- Wilmington, DE
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Incyte advertising spend, FY2018-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 10, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/incyte/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies